Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1629 1654 1674
This examiner grants 68% of resolved cases
Anthony Joseph Seitz is an examiner in Tech Center 1600 and Art Unit 1629. He has managed 208 resolved cases. The allowance rate for these cases is 68.3 percent. This 68.3 percent rate provides a measure of how often applications result in a patent grant. Practitioners can use this 208-case history to understand the examiner's general tendencies.
The interview lift is 27.0 percent. This 27.0 percent figure represents the difference in allowance probability when an interview is conducted. A positive value like 27.0 percent indicates that interviews are associated with an increase in the likelihood of allowance. This suggests that requesting an interview is a productive strategy for this docket.
The median days to allowance is 1250. This 1250-day duration is the middle value for the time from filing to grant. For applicants, this 1250-day median is a key metric for planning the prosecution timeline. By combining the 68.3 percent allowance rate with the 1250-day median, practitioners can develop a data-grounded strategy for Art Unit 1629.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18258653 | USE AS SELECTIVE AGONIST OF MELANOCORTIN-4 RECEPTOR | Final Rejection | LG CHEM, LTD. |
| 17599207 | BRYOSTATIN COMPOUNDS FOR ENHANCEMENT OF IMMUNOTHERAPY | Non-Final OA | The Board of Trustees of the Leland Stanford Junior University |
| 18255655 | METHODS OF TREATING AND PREVENTING KIDNEY DISEASE | Non-Final OA | Washington University |
| 17770704 | USE OF IMIDAZOPYRIMIDINE OR IMIDAZOTRIAZINE COMPOUND FOR PREVENTION, ALLEVIATION, OR TREATMENT OF DEVELOPMENTAL DISABILITY | Non-Final OA | SK BIOPHARMACEUTICALS CO., LTD. |
| 17618838 | DIBENZYLAMINES AS AMINO ACID TRANSPORT INHIBITORS | Final Rejection | VANDERBILT UNIVERSITY |
| 18546830 | COMPOSITION FOR TREATMENT OF ANTICANCER DRUG RESISTANCE | Non-Final OA | INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YONSEI UNIVERSITY |
| 18344560 | CD73 COMPOUNDS | Non-Final OA | Gilead Sciences, Inc. |
| 18383708 | PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR GAMMA (PPARy) LIGANDS AND METHODS OF USE AS TREATMENTS FOR INSULIN RESISTANCE, OBESITY, FATTY LIVER DISEASE, AND TYPE 2 DIABETES | Non-Final OA | The Board of Regents of the University of Oklahoma |
| 18281440 | METHODS FOR IMPROVING POULTRY HEALTH | Non-Final OA | CORNELL UNIVERSITY |
| 18482497 | BETA-2 ADRENORECEPTOR MODULATORS AND METHODS OF USING SAME | Non-Final OA | Thomas Jefferson University |
| 18476063 | HETEROCYCLIC COMPOUNDS AS E3 LIGASE INHIBITORS | Final Rejection | Accutar Biotechnology Inc. |
| 17672693 | COMPOSITIONS AND METHODS FOR MONITORING, DIAGNOSIS, PROGNOSIS, DETECTION, AND TREATMENT OF CANCER | Non-Final OA | Rakesh K. Srivastava |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy